Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat z nowo rozpoznanym rakiem piersi typu HR+, HER2+ (wcześniej nieleczonym)
- •Terapia hormonalna może być rozpoczęta do 28 dni przed włączeniem do badania i musi być rozpoczęta przed chemioterapią
- •Nowotwór w stadium IIA-IIIC, wymaga co najmniej 4 cykli chemioterapii
- •Potwierdzenie typu raka (Luminal A, Luminal B lub HER2-wzbogacony) na podstawie badania MammaPrint/BluePrint
✗ Disqualifies
- •Wiek poniżej 18 lat, ciąża, pozbawienie wolności, zaburzenia zdolności do podejmowania decyzji
- •Inne nowotwory złośliwe (nie piersi) w ciągu ostatnich 2 lat
- •Rak piersi w ciągu ostatnich 5 lat
- •Nawrót raka piersi
- •Rak piersi w stadium IV (rozsiany)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Legacy Mount Hood Medical Center
Gresham, United States
Legacy Good Samaritan Medical Center
Portland, United States
Legacy Meridian Park Medical Center
Tualatin, United States
Legacy Salmon Creek Medical Center
Vancouver, United States
Trial contact
Legacy Oncology Clinical Research
Legacy Oncology Research
Legacy Oncology Clinical Research
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.